1. Home
  2. TONX vs KRRO Comparison

TONX vs KRRO Comparison

Compare TONX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TONX

TON Strategy Company

HOLD

Current Price

$3.98

Market Cap

134.0M

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$13.05

Market Cap

150.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TONX
KRRO
Founded
N/A
2014
Country
United States
United States
Employees
23
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.0M
150.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
TONX
KRRO
Price
$3.98
$13.05
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
543.3K
114.0K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.26
N/A
Revenue Growth
N/A
181.46
52 Week Low
$1.75
$5.20
52 Week High
$8.23
$55.89

Technical Indicators

Market Signals
Indicator
TONX
KRRO
Relative Strength Index (RSI) 62.85 58.48
Support Level $2.96 $9.51
Resistance Level $4.31 $14.52
Average True Range (ATR) 0.48 0.95
MACD 0.03 0.32
Stochastic Oscillator 85.50 85.42

Price Performance

Historical Comparison
TONX
KRRO

About TONX TON Strategy Company

TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: